RxDoctor Payments Data

Kathryn Michalczyk, MD

Family Medicine · Goshen, INNPI 1528296373

Payments from drug & device makers

$259in general payments, 2019–2025

Across 15 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$47
  • Pfizer$46
  • VBI Vaccine (delaware) Inc.$29
  • Novo Nordisk$27
  • Itamar Medical Inc$25
  • AbbVie$19
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi Pasteur Inc.3$47
Pfizer3$46
VBI Vaccine (delaware) Inc.1$29
Novo Nordisk2$27
Itamar Medical Inc1$25
AbbVie1$19
Lilly USA, LLC1$19
Amgen1$17
GSK1$16
Hologic Sales And Service, LLC1$15

How this compares

$259 in reported general payments places this provider in the 35th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$121,464
Medicare patients
247
Services billed
2,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$68,737
JardianceEmpagliflozin39$42,867
MounjaroTirzepatide27$34,877
RybelsusSemaglutide14$33,692
EliquisApixaban29$33,173
AbrysvoRsv Vacc, Pref A And Pref B/Pf51$16,198
XareltoRivaroxaban12$13,441
Combivent RespimatIpratropium/Albuterol Sulfate14$8,926
Tresiba Flextouch U-100Insulin Degludec24$7,745
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,281
Synjardy XrEmpagliflozin/Metformin Hcl13$6,318
ShingrixVaricella-Zoster Ge/As01b/Pf26$5,644
Atrovent HfaIpratropium Bromide12$5,571
SymbicortBudesonide/Formoterol Fumarate20$4,670
Cyclosporine14$2,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$27$102,42957 claims
PfizerEliquis, Abrysvo$46$49,37080 claims
Lilly USA, LLCMounjaro$19$34,87727 claims
GSKShingrix$16$5,64426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Goshen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →